The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Training (Career Development) Component will use CEGIR resources and opportunities available at each site to create a program that will train new investigators in clinical and translational research, designed to ultimately enhance the likelihood of academic success for the investigators in training. This consortium represents an unparalleled opportunity for new clinical investigators to obtain training in the rare diseases eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC) and to enhance their career development. Each CEGIR site has experience and resources to aid career development of new investigators in clinical investigation and translational research and has new investigators that would be outstanding CEGIR Trainee candidates. The specific goals ofthe CEGIR Training (Career Development) Component are 1) to enable CEGIR Trainees to become independent clinical and/or translational investigators;2) to aid CEGIR Trainees in developing a broad understanding ofthe basic, translational, and clinical science pertinent to the immunobiology, pathogenesis, and genetics of EoE, EG, and EC via didactic instruction;and 3) to facilitate CEGIR Trainee networking and integration in the EoE, EG, and EC research community. These goals will be achieved through a variety of important interventions including recruiting stellar candidates, encouraging inclusion of underrepresented minorities, didactic lectures, the Biannual CEGIR Education Symposium, interactions with established researchers and patient advocacy groups (PAGs) in EoE, EG, and EC, opportunities to visit centers of excellence to learn new techniques, and active involvement in other research activities of CEGIR.
Increasing the number and quality of clinician researchers studying eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis will improve current and future patient care. We will train clinician researchers about these rare diseases while enhancing the understanding and treatment of them throughout the community. Ultimately, this training is designed to improve patient outcomes while advancing the development of a cure.
|Mehta, Pooja; Sundaram, Shikha; Furuta, Glenn T et al. (2016) Propofol Use in Pediatric Patients With Food Allergy and Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr :|
|Molina-Infante, Javier; Bredenoord, Albert J; Cheng, Edaire et al. (2016) Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut 65:524-31|
|Imam, Tanbeena; Gupta, Sandeep K (2016) Topical glucocorticoid vs. diet therapy in eosinophilic esophagitis: the need for better treatment options. Expert Rev Clin Immunol 12:797-9|
|Kliewer, Kara L; Venter, Carina; Cassin, Alison M et al. (2016) Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet? J Allergy Clin Immunol 137:1011-4|
|Morris, David W; Stucke, Emily M; Martin, Lisa J et al. (2016) Eosinophil progenitor levels are increased in patients with active pediatric eosinophilic esophagitis. J Allergy Clin Immunol 138:915-918.e5|
|Watts, Abhishek; Alexander, Jeffrey A; Gupta, Sandeep K (2016) Eosinophilic esophagitis: search for noninvasive techniques for long-term monitoring. Gastrointest Endosc 83:307-8|
|Hill, David A; Spergel, Jonathan M (2016) The Immunologic Mechanisms of Eosinophilic Esophagitis. Curr Allergy Asthma Rep 16:9|
|Gonsalves, Nirmala; Furuta, Glenn T; Atkins, Dan (2016) Eosinophilic Gastrointestinal Disorders Affect More Than Just the Esophagus. J Pediatr Gastroenterol Nutr 62:1-2|
|Nguyen, Nathalie; Furuta, Glenn T; Masterson, Joanne C (2016) Deeper Than the Epithelium: Role of Matrix and Fibroblasts in Pediatric and Adult Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr 63:168-9|
|Rawson, Renee; Yang, Tom; Newbury, Robert O et al. (2016) TGF-Î²1-induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis. J Allergy Clin Immunol 138:791-800.e4|
Showing the most recent 10 out of 37 publications